Homepage Link

Q&A

For further information and clarity on our project, please see our Q&A below!

Have questions about the WISH Revolution? Look no further.

We've compiled a list of common technical questions about the project and our responses to them.

The Big Picture:

  • Jun 17, 2020

    Q: At what level of health care will the WISH model be implemented?

    The WISH package of services will be integrated into the existing primary health care system in implementing countries and adapted or tailored for the diverse types of facilities and community-based services available in that country, for example, health posts, or door to door visits. It will be integrated into health care services for women, particularly reproductive health and HIV services that are provided within the essential package of care.
  • Q: What is the strategy for the integration of WISH into existing health care systems?

    The WISH model will be added to a well-functioning line of women’s health services during the early stages (vertical integration), and then integrated more broadly across the healthcare system (horizontal integration) for sustainability. Training and skill-building such as just-in-time or in-service training will be used for practicing providers in early implementation. Over time, capacity and skill development will be shifted to pre-service training of providers who are new to these practices. Similarly, initial integration will address changes in clinical care flow or community-based care, as well as equipment supply and maintenance with short term solutions. Longer term broader and sustainable integration will be informed by the lessons learned in the process of initial integration.

  • Q: How will the WISH team address sustainability?

    Members of the WISH team have a long history of effectively working with key stakeholders of local and national governments in Peru and Kenya, our priority sites, as well as across Africa, Asia and South America. We will work with Ministry-led Technical Working Groups or subnational provincial or district leaders to tailor our approach to country-specific proven methods. We will address the inclusion of costs into the appropriate national or subnational budgets, and work to address any policy or scope of practice changes needed to assure inclusion in national essential packages of care. In addition, the team will establish a supply chain pathway for the technologies and ancillary supplies and create protocols for workforce pre-training.

  • Q: How will the WISH team facilitate scale?

    As we scale beyond individual countries, we will work with international organizations like WHO, especially those with country representatives, as well as relevant private sector or NGO groups that are providing women’s healthcare, to address training and equipment supply chain issues for broader implementation. Further, we will ensure the inclusion of private sector providers of women’s health care (for example, NGOs), especially at the community level, into Ministry training and systems to meet their needs.   

  • Jun 17, 2020

    Q: How are women in the target population co-creating the WISH model?

    Members of the WISH team have successfully demonstrated the effectiveness of a women centered model for self-HPV screening test for cervical cancer, in which women in the target population co-create models for training, delivery and education and then become front line workers within that community. This model empowers women in the community to reframe the solutions for cervical cancer screening in their own terms.  This is the strategy that will be used across health care providers including midwives, nurses and community health providers.

  • Jun 17, 2020

    Q: What evidence is there to support that peer to peer networks translate to agency and empowerment?

    There is on-the-ground evidence for the effectiveness of peer to peer networks translating to improved self-advocacy and consequently improved health outcomes. There are many examples of this globally – two specific cases worth noting are the Mothers to Mothers program which hires women with HIV to counsel and provide care for other women with HIV in their community and the HOPE program, developed by a member of the WISH team, which uses the same model as Mothers to Mothers to employ women in the community to educate and empower their peers to self-screen for cervical cancer.

  • Jun 17, 2020

    Q: What are the ways in which the WISH team is using story telling through peer to peer networks to increase agency?

    There are several ways in which we have already used storytelling to create agency in the context of cervical cancer prevention. Through one on one interactions with community health providers, women are able to understand why it is important to seek preventative care before symptoms occur. We have also held educational workshops, led by a local midwife, bringing women together in the local community center to have a broader group discussion about cervical cancer and providing an opportunity to discuss their questions. In addition to in-person interactions, we have compiled Whatsapp recording videos from women who have cervical cancer, women who have been able to prevent cancer through preventative care and community health providers (women) who have delivered care.

  • Jun 17, 2020

    Q: What is the age range during which women should be screened?

    The recommended age range for screening is between 30 and 50 years. However, in HIV prevalent populations which are at increased risk for cervical cancer, the recommended age of screening can start as early as 21 years of age.

  • Jun 17, 2020

    Q: Will intensive treatment therapies for invasive cervical cancer, such as radiation, be incorporated into the model?

    The software and cloud services that we create will be directly linked to district and tertiary hospitals through referral agreements. Additionally, confirmation of patient referral and placement will be set up in the software.  In the short term, digital linkages will be supported by physical interactions to reduce the number of missed cases or delayed referrals.  Simultaneously, direct follow up with patients either in-person or text to assess both successful follow-up as well as compliance. In the longer term, these processes will be used as quality control measures for continual refinement of the referral process.  

  • Jun 17, 2020

    Q: Don’t men get HPV as well? Why are they not included in this model? What about oral and anal cancers?

    HPV is prevalent not only in women, but also in men. In addition, it is a precursor for oral and anal cancers which affect both genders. The model we have created focuses on cervical cancer, an international priority, for which we have created innovative technologies and delivery strategies. Proving the impact of this patient-centered framework to cancer prevention is essential to and will benefit other cancers, particularly, anal cancers which occur in marginalized populations that suffer from barriers associated with shame and stigma.

  • Jun 17, 2020

    Q: How will the potential for increased stigma and fear attributed to the introduction of new technologies be addressed?

    The co-creation of implementation strategies adapted to each country and community, as well as the iterative process we use, will ensure that the technologies introduced through WISH will be adopted and empower women, rather than exacerbate shame and stigma. We have already had experience in multiple countries in South America, Africa and North America which have shown us that women from both urban and rural communities have a powerful and positive response to the technologies we have introduced that give them privacy and control over their own bodies.

  • Jun 17, 2020

    Q: Why is expertise in oral history important for the WISH model?

    Expertise in oral history will ensure that the project will incorporate well-established methodologies to capture women’s histories.  Specifically, the methodologies will be used to minimize the influence of unconscious bias or cultural factors, that could confound the authentic narratives of the women who participate.

  • Jun 17, 2020

    Q: How can device misuse, improper reprocessing, and theft be prevented?

    The WISH team will create training and quality control processes to promote accountability and ownership in order to minimize improper handling or misuse of the technologies that have been introduced into the communities. The peer to peer network is again important in this regard as has been shown with the HOPE cervical cancer screening model implemented by a WISH team member.  In the rural communities in which HOPE operates, women with little or no academic credentials are trained and equipped as empowered peer leaders who collectively ensure that their peers adhere to the best practices, particularly when their livelihoods depend on this responsibility.

  • Jun 17, 2020

    Q: What is the payment structure for this model?

    Short term support for the WISH model will be through international donors, foundations and government faders. When possible, community-based models may be used to create sustainable jobs in which local health providers can charge a small fee for their services, which has been demonstrated to be an extremely cost-effective way to disseminate community-based care. In the longer-term, the WISH model will be integrated into essential care packages or services that are incorporated into subnational budgets at provincial, state or district levels to cover service costs. 

Regarding peer-to-peer learning...

  • Q: What evidence supports the impact of using "experience sharing" and "public narration" to reduce stigma?

    Narratives and narrative-driven health messaging and communication of prevention programs are a useful tool in reducing health-related stigma [1].

    Digital storytelling has been shown to reduce stigma around mental health, obesity, and many other pressing public health concerns [2]. These methods can be applied to HPV and cervical cancer education within the WISH model.

    [1] Sheila T. Murphy, Lauren B. Frank, Joyee S. Chatterjee, Meghan B. Moran, Nan Zhao, Paula Amezola de Herrera, and Lourdes A. Baezconde-Garbanati, 2015: Comparing the Relative Efficacy of Narrative vs Nonnarrative Health Messages in Reducing Health Disparities Using a Randomized Trial American Journal of Public Health 105, 2117_2123
    [2] Davidson, T., Moreland, A., Bunnell, B. E., Winkelmann, J., Hamblen, J. L., & Ruggiero, K. J. (2018). Reducing stigma in mental health through digital storytelling. In B. A. Canfield & H. A. Cunningham (Eds.), Advances in psychology, mental health, and behavioral studies (APMHBS) book series. Deconstructing stigma in mental health (p. 169–183). Medical Information Science Reference/IGI Global. https://doi.org/10.4018/978-1-5225-3808-0.ch007https://doi.org/10.2105/AJPH.2014.302332

  • Q: What evidence from viral studies support the positive impacts of "public narration"?

    Experience sharing and public narration methods such as "perspective-taking" narration where individuals embody the personal stories of their peers living with HIV have been proven to reduce stigma associated with HIV [1]. Experience sharing reduces stigma of HIV facility staff, nurses, and providers improving quality and access to care [2].

    [1] Adrienne H. Chung, Michael D. Slater, Reducing Stigma and Out-Group Distinctions Through Perspective-Taking in Narratives, Journal of Communication, Volume 63, Issue 5, October 2013, Pages 894–911, https://doi.org/10.1111/jcom.12050
    [2] Nyblade, L., Srinivasan, K., Mazur, A., Raj, T., Patil, D. S., Devadass, D., … Ekstrand, M. L. (2018). HIV Stigma Reduction for Health Facility Staff: Development of a Blended- Learning Intervention. Frontiers in Public Health, 6. doi: 10.3389/fpubh.2018.00165

  • Q: What evidence supports the success of the HOPE model?

    Of the 2,090 women screened, 12.8% or 266 women tested positive for HPV infection. The average time taken between the distribution of the kits to laboratory examination was 10 days. A total of 260 women who tested positive were followed up and 252 consented to have a colposcopy, Pap test and biopsy. Additionally, a total of 179 women who tested negative were followed up with a colposcopy, Pap test and biopsy. Of these 431 women (both HPV-positive and -negative), 49 women had either high-grade lesions, in situ cancer or other adenocarcinomas. A total of 37 were treated using cryotherapy, while 12 were treated using other procedures (LEEP, hysterectomy and/or radiotherapy). The project received additional funding and support of $10,000 from the Weill Cornell Medical College to purchase a colposcope, to be placed at the Bahia Blanca Health Centre.

    Source: HOPE - Human papillomavirus screening to improve women´s life. (n.d.). Retrieved from https://www.grandchallenges.ca/grantee-stars/0686-01-10/

Have a Question You'd Like Answered?

Please enter your name.
Please enter a valid email.
Please enter a message.